Physician profile
Haley Hoy
NPI 1265564561
$368,433.33
in general payments reported to CMS, 2019-2025
19 companies · $180K in 2025
The $180K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $6,165 · 2023: $34K · 2024: $137K · 2025: $180K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $267K · Travel and Lodging: $54K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $14K · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $266,613.82 |
| Travel and Lodging | $53,656.18 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,206.50 |
| Food and Beverage | $13,666.27 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $320,825.68 | 2022-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43,202.59 | 2021-2025 | Ofev, Spiriva Respimat, Jascayd |
| Genzyme Corporation | $1,641.38 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $446.05 | 2023-2025 | Acthar, Terlivaz |
| Genentech, INC. | $378.96 | 2022-2025 | Xolair |
| Novo Nordisk INC | $312.95 | 2021-2025 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $250.00 | 2025 | Breztri |
| Alexion Pharmaceuticals, INC. | $235.44 | 2024-2025 | Ultomiris |
| Inspire Medical Systems, INC. | $143.77 | 2025 | Inspire |
| Amgen INC. | $139.48 | 2025 | |
| Veloxis Pharmaceuticals, INC. | $137.64 | 2021-2022 | |
| Edwards Lifesciences Corporation | $135.45 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Blueprint Medicines Corporation | $122.99 | 2023 | Ayvakit |
| Actelion Pharmaceuticals US, INC. | $121.37 | 2025 | Uptravi, Opsumit |
| Ardelyx, INC. | $117.72 | 2025 | Xphozah 30 Mg |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $110.00 | 2022 | |
| Insmed, INC. | $87.66 | 2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $21.50 | 2025 | Glassia |
| Adma Biomanufacturing LLC | $2.70 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Hoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.